| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BL-M11D1 | BL-M11D1 | Phase 3 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| BI-836858 | BI-836858 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CART-33 (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details | |
| Lintuzumab Ac-225 | AC225-MOAB-M195; HuM195-Ac-225; 225Ac-HuM-195 | Phase 2 Clinical | Pdl Biopharma Inc | Glioblastoma; Glioma; Gliosarcoma; Leukemia, Myeloid, Acute; Multiple Myeloma | Details |
| CLL1/CD33/CD38/CD7 CAR-T cell therapy | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Universal donor derived CD33 CAR-NK cell therapy (Nationwide Children'S Hospital) | Phase 2 Clinical | Nationwide Children'S Hospital | Leukemia, Myeloid, Acute | Details | |
| CD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Leukemia, Myeloid | Details | |
| VBP-301 | VBP301; VBP-301 | Phase 2 Clinical | Vor Biopharma Inc | Leukemia, Myeloid, Acute | Details |
| VBP-101 | VBP101; VBP-101 | Phase 2 Clinical | Vor Biopharma Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech) | BAH244; BAH-244 | Phase 2 Clinical | Essen Biotech | Leukemia, Myeloid, Acute | Details |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| CD33 CAR T Cells(Beijing Boren Hospital) | Phase 2 Clinical | Beijing Gao Boren Hospital Co Ltd | Leukemia; Leukemia, Myeloid, Acute; Neoplasms | Details | |
| Emerfetamab | AMG-673; AMG673 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| AL-003 | AL-003 | Phase 1 Clinical | Abbvie Inc, Alector Inc | Alzheimer Disease | Details |
| PRGN-3006 | PRGN-3006; PRGN-3006 UltraCAR-T | Phase 1 Clinical | Precigen Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| anti-CD33 (FL-33) CAR T-cell therapy (Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing Gao Boren Hospital Co Ltd | Leukemia, Myeloid, Acute | Details | |
| anti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| ORM-6151 | ORM-6151; BMS-986497 | Phase 1 Clinical | Orum Therapeutics Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CD33Bi FPBMC (University Of Virginia) | Phase 1 Clinical | University Of Virginia | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases | Details | |
| A-CAR028 | A-CAR028 | Phase 1 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Leukemia, Myeloid, Acute | Details |
| ACLX-004 | ACLX-004 | Phase 1 Clinical | Arcellx Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| JNJ-89853413 | JNJ-89853413 | Phase 1 Clinical | Janssen Research & Development Llc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| GTB-3650 | GTB-3650; GTB-360; OXS-3350; OXS-C3550 | Phase 1 Clinical | Masonic Cancer Center, University Of Minnesota | Bone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| RJK-RT2831 | RJK-RT2831; RJKRT2831; RT-2831; RT2831 | Phase 1 Clinical | Nanjing RegeneCore Biotech Co Ltd | Hematologic Neoplasms | Details |
| JNJ-67571244 | JNJ-1244; JNJ-67571244; JNJ-67371244 | Phase 1 Clinical | Johnson & Johnson | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CD33-NKE | CD33-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Leukemia, Myeloid, Acute | Details |
| Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan) | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Leukemia, Myeloid, Acute; Neoplasm, Residual | Details | |
| CD33 CAR-NK cell therapy (Hangzhou Qihan) | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Leukemia, Myeloid, Acute; Neoplasm, Residual | Details | |
| Eluvixtamab | AMG-330; MT-114 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| Anti-CD33 chimeric antigen receptor T cell therapy (Shanghai YaKe/Zhejiang University) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| anti-CD33 CAR T cells therapy(iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Lintuzumab Ac-225/Venetoclax | Phase 1 Clinical | Actinium Pharmaceuticals Inc | Leukemia, Promyelocytic, Acute | Details | |
| SC-DARIC33 | SC-DARIC33; DARIC-33 | Phase 1 Clinical | Genetix Biotherapeutics Inc | Leukemia, Myeloid, Acute | Details |
| DXC-007 | DXC-007 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Lintuzumab-gelonin conjugate | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details | |
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemtuzumab ozogamicin | CMA-676; CDP-771; WAY-CMA-676; CL-555201; hP67.6-calicheamicin | Approved | Pfizer Inc, Ucb Sa | Mylotarg | Japan | Leukemia, Myeloid, Acute | Pfizer Inc | 2008-01-18 | Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes | Details |


